Arbutus Biopharma (ABUS) Deferred Taxes (2014 - 2019)

Arbutus Biopharma (ABUS) has reported Deferred Taxes for 6 consecutive years, with -$12.7 million the latest figure, recorded in Q3 2019.

• Quarterly Deferred Taxes fell 195.68% year-over-year to -$12.7 million in Q3 2019, while the trailing twelve-month figure through Dec 2020 was -$12.7 million (up 25.27% YoY) and the FY2019 annual result came in at -$12.7 million, down 195.68% from the prior year.
• Deferred Taxes slipped to -$12.7 million in Q3 2019 per ABUS's latest filing, from -$4.3 million in the prior quarter.
• Over the last five years, Deferred Taxes for ABUS reached as high as $744000.0 in Q3 2017 and fell as low as -$64.9 million in Q2 2016.
• A 5-year average of -$20.3 million and a median of -$13.9 million in 2015 frame the typical range for Deferred Taxes.
• Annual changes were most pronounced in 2016 — Deferred Taxes sank 3964.41% — and 2017, when it soared 37.65%.
• Year by year, Deferred Taxes stood at -$989000.0 in 2015, then plunged by 3964.41% to -$40.2 million in 2016, then surged by 37.65% to -$25.1 million in 2017, then surged by 82.92% to -$4.3 million in 2018, then slumped by 195.68% to -$12.7 million in 2019.
• According to Business Quant data, Deferred Taxes over the past three periods registered -$12.7 million, -$4.3 million, and -$25.1 million for Q3 2019, Q3 2018, and Q4 2017 respectively.